Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06535607
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With AdvancedMetastatic Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With AdvancedMetastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
eVOLVE-02
Brief Summary:
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advancedmetastatic solid tumors
Detailed Description:
eVOLVE-02 study will evaluate volrustomig monotherapy or volrustomig-based combination therapy in various advanced or metastatic solid tumors Data from this Phase II platform study will inform future Phase III studies
In sub-study 1 volrustomig will be evaluated as monotherapy in approximately 30 evaluable participants with cervical cancer
In sub-study 2 volrustomig will be evaluated as monotherapy in approximately 30 evaluable participants with head and neck squamous cell carcinoma
In sub-study 1 volrustomig will be evaluated as monotherapy in approximately 30 evaluable participants with cervical cancer
In sub-study 2 volrustomig will be evaluated as monotherapy in approximately 30 evaluable participants with head and neck squamous cell carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None